Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wellpoint Prilosec program

This article was originally published in The Tan Sheet

Executive Summary

Wellpoint expands availability of its discount program for the OTC proton pump inhibitor into Virginia in August with "other geographies to follow," the insurer says during second quarter earnings call. The initiative "allows members, with a doctor's consent, to access a 90-day supply of Prilosec OTC for $16, considerably less than their prescription drug co-payment." Wellpoint launched the coupon plan in California and Georgia in 2003 (1"The Tan Sheet" Aug. 25, 2003, p. 6). The provider has advocated Rx-to-OTC switches in certain categories to lower healthcare costs...

You may also be interested in...

WellPoint NextRx/BCBS Pilot Program Encourages Members To Buy OTC

Insurers are increasingly encouraging members to use over-the-counter drugs in place of more expensive prescription options by expanding coverage plans, offering coupons or paying for a member's first supply of an OTC drug. The growing trend reflects a push to contain rising health care costs

Novartis Omeprazole Offering, Wellpoint, Prilosec OTC Pressure PPI Prices

Novartis' entrance into the OTC loratadine market in March could set a precedent for the firm to make a similar move with the proton pump inhibitor omeprazole

Alvotech FDA Approval Clears Path To Challenge Humira

Alvotech and US marketing partner Teva can now launch “imminently” their long-planned rival to Humira, with the firms believing that the Simlandi biosimilar will stand out from the crowd of other adalimumab challengers thanks to a unique combination of product attributes.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts